===========================================================
Please Ignore this mail if you didn’t sign up for the APSC 2018 congress System
============================================================
Dear Dr. kazuhiro Ueno,
On behalf of the APSC 2018 Organizing Committee, we thank you for your participation in the congress. Your abstract has been submitted successfully. Please check the information below for accuracy. You may revise your submitted abstract before the deadline at 23:59, January 12, 2018 (GMT+8) (GMT+8).
Please note that at least one author of an accepted abstract should register and complete the full payment prior to 23:59, February 27, 2018 (GMT+8), in order to be included in the program of APSC 2018.
Thank you again for the submission.
For any further inquiries, please do not hesitate to contact the Congress Secretariat Office.
Sincerely yours,
APSC 2018 Congress Secretariat
Angela Chen
Tel: +886-2-2798-8329 Ext.38
Fax: +886-2-2798-6225
E-mail: system@apsc2018.tw
- Reference Number
P9-003
- Affiliation(s)
| Display Order | Title of Affiliation |
| 1 | Ueno Cardiovascular Medical clinic |
- Presenting Author
| Display Order | First Name | Last Name | Country | Affiliation | |
| 1 | Kazuhiro | Ueno | kmtsueno@samba.ocn.ne.jp | Japan | Ueno Cardiovascular Medical clinic |
- Co-author(s)
| Display Order | First Name | Last Name | Country | Affiliation |
- Presenting Type Selection
Poster
- Category Selection
Diabetes
- Award Application
- Abstract Review
Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Left Ventricular Function in Patients with Type 2 Diabetes Mellitus
Kazuhiro Ueno1
1Ueno Cardiovascular Medical clinic
Background: Recent clinical studies showed that sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) reduced cardiovascular events in patients with type 2 diabetes mellitus (T2DM).But effect of SGLT2-Is on left ventricular (LV) function is unknown. In this study, we investigated whether SGLT2-Is improve LV function.
Methods and Result: We studied 35 T2DM patients (16male, 19female, average of age 67.6years). Transthoracic echocardiograms and Speckle Tracking Echocardiography (STE) were performed before and 6 months after initiation of SGLT2-Is (15 Empagliflozin, 20 Ipragliflozin). SGLT2-Is treatments improved glycemic control, blood pressure and body weight significantly [HbA1c:7.5% vs 7.0%, BW 69.2kg vs 66.4kg, BP: 132.9/74.6mmHg vs 122.9/68.7mmHg]. Echocardiogram and STE parameters showed no significant change between before and after SGLT2-Is initiation [LVDd: 47.4mm vs 47.5mm, LVEF: 63.9% vs 64.5%, e’: 5.7cm/s vs 5.9cm/s, GLS:-18.5% vs -18.5%].
Discussion and Conclusion: In this study, SGLT2-Is treatments did not improve LV function significantly in patients with T2DM. It is speculated that SGLT2-Is improve cardiovascular prognosis by indirect effect such as lowering blood pressure.